Biote to Present at Jefferies London Healthcare Conference

Rhea-AI Summary

Biote Corp. (Nasdaq: BTMD) has announced its participation in the Jefferies London Healthcare Conference from November 15-17, 2022. CEO Terry Weber will present on November 15, 2022, at 12:20 p.m. local time, followed by a Q&A session with CFO Samar Kamdar. A live audio webcast of the presentation will be available here. Biote specializes in personalized hormone therapy, targeting a $7 billion market in preventive healthcare.

IRVING, Texas--(BUSINESS WIRE)-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced its participation in the Jefferies London Healthcare Conference, November 15-17, 2022, in Aldwych, London.

Biote Chief Executive Officer, Terry Weber, will present at the conference on November 15, 2022 at 12:20 p.m. local time. Samar Kamdar, Chief Financial Officer, will be available to answer questions following the presentation.

A live audio webcast of the presentation will be available at the following link:

https://wsw.com/webcast/jeff255/btmd/1841697

Following the conference, the webcast replay will be available for 90 days following the live event in the Events section of the Company’s Investor Relations website at https://ir.biote.com.

About Biote

Biote is transforming healthy aging through innovative, personalized hormone optimization therapies delivered by Biote-certified medical providers. Biote trains practitioners how to identify and treat early indicators of hormone-related aging conditions, an underserved $7 billion global market, providing affordable symptom relief for patients and driving clinic success for practitioners.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “may,” “can,” “should,” “will,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “hope,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “might,” “ongoing,” “potential,” “predict,” “would” and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers’ reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers’ sensitive to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; our limited operating history; our ability to protect our intellectual property; the unpredictability of the effects of the COVID-19 pandemic; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Biote’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 and other documents filed by Biote from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005171/en/

Media:

Press@biote.com



Investor:

IR@biote.com

Source: biote Corp.

FAQ

What is Biote Corp's stock symbol?

Biote Corp's stock symbol is BTMD.

When will Biote Corp present at the Jefferies London Healthcare Conference?

Biote Corp will present at the Jefferies London Healthcare Conference on November 15, 2022, at 12:20 p.m. local time.

Where can I watch Biote Corp's presentation at the Jefferies Conference?

You can watch Biote Corp's presentation via a live audio webcast available here.

What is Biote Corp's focus in healthcare?

Biote Corp focuses on preventive healthcare through personalized hormone therapy.

What market does Biote Corp aim to address?

Biote Corp aims to address the $7 billion global market for hormone-related aging conditions.